Peng Luan
5 Papers
21 Citations
Peng Luan is an academic researcher. The author has contributed to research in topics: Medicine & Janus kinase. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu,Francis DeGuzman,Stanley J. Hollenbach,Mark Karbarz,Keith Abe,Gail Lee,Peng Luan,Athiwat Hutchaleelaha,Mayuko Inagaki,Pamela B. Conley,David Phillips,Uma Sinha +11 more
TL;DR: In this article, a modified form of coagulation factor Xa (fXa) was used as an antidote for fXa inhibitors and corrected the prolongation of ex vivo clotting times by such inhibitors.
735
Nucleolar URB1 ensures 3′ ETS rRNA removal to prevent exosome surveillance
Lin Shan,Guang Xu,Run-Wen Yao,Peng Luan,Youkui Huang,Peipei Zhang,Lin Zhang,Xiang Gao,Ying Li,Shi-Meng Cao,Shuai-Xin Gao,Zheng-Hu Yang,Siqi Li,Liang-Zhong Yang,Ying Wang,Catharine C L Wong,Li Yu,Jinsong Li,Li Yang,Ling-Ling Chen +19 more
TL;DR: Insight is provided into functional sub-nucleolar organization and a physiologically essential step in rRNA maturation that requires the static protein URB1 in the phase-separated nucleolus is identified.
50
•Journal Article
Abstract 12420: Reversal of Low Molecular Weight Heparin and Fondaparinux by a Recombinant Antidote (r-Antidote, PRT064445)
Genmin Lu,Francis DeGuzman,Stanley J. Hollenbach,Peng Luan,Keith Abe,Gail Siu,Pamela B. Conley,David Phillips,Uma Sinha +8 more
TL;DR: Anticoagulants, including indirect factor Xa (fXa) inhibitors low molecular weight heparin (LMWH) and fondaparinux, are widely used for the treatment and prevention of thrombosis but have the potential to be abused.
15
Patent
Targeted delivery and expression of procoagulant hemostatic activity
Peter J. Sims,Pamela B. Conley,Peng Luan,David R. Phillips +3 more
- 27 Mar 2008
TL;DR: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a platelet scramblase, has been developed.
4
Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK.
Greg Coffey,Peng Luan,Suzanne M. Delaney,Anjali Pandey,Zhaozhong Jia,Qing Xu,Bauer Shawn M,Yonghong Song,Pamela B. Conley,David Phillips,Uma Sinha +10 more
TL;DR: Assays using the non-Hodgkin's lymphoma B cell lines Ramos, SUDHL-4 and -6 showed that each compound inhibited BCR-induced Syk auto-phosphorylation and BLNK phosphorylation as well as subsequent Ca2+ flux and ERK phosphorylated, suggesting that the specific inhibition of Syk, without concomitant inhibition of JAK, may be sufficient for the treatment of non- Hodgkins lymphoma.
2